Home » Topics » BioWorld Science

BioWorld Science
RSS

SENS-401 shows good local bioavailability in sensorineural hearing loss model

Feb. 9, 2022

Xanadu signs agreements with Yale to support development of intranasal SARS-CoV-2 vaccine booster

Feb. 9, 2022

Immunome's antibody cocktail effective against live versions of SARS-CoV-2 Omicron variant in vitro

Feb. 9, 2022

MDL-001 significantly reduces SARS-CoV-2 viral load in lungs in preclinical study

Feb. 9, 2022

Eisai divulges new OX2 receptor agonists for narcolepsy

Feb. 9, 2022

Caregen identifies new antivirals for SARS-CoV-2

Feb. 9, 2022

Korean researchers synthesize PDE5A and HDAC6 dual inhibitors for Alzheimer's

Feb. 9, 2022

Nanjing Zhengxiang Pharmaceuticals divulges DHODH inhibitors

Feb. 9, 2022

IFM Due patents hSTING antagonists for cancer

Feb. 9, 2022

Non-muscle-targeted AAV8/DC190-ASM gene therapy for treating limb girdle muscular dystrophy 2B

Feb. 9, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...